Wharton’s Jelly Derived Mesenchymal Stromal Cell Therapy (Celltech Pharmed/Royan Stem Cell Technology)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameWharton’s Jelly Derived Mesenchymal Stromal Cell Therapy (Celltech Pharmed/Royan Stem Cell Technology)
Drug Alias NameRecurrent Umbilical Cord-Derived Mesenchymal Stem Cell Therapy (Celltech Pharmed/Royan Stem Cell Technology)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Stem cell therapy > Umbilical cord stem cell therapy
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIran
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelltech
China Registration ClassN/A

Develop Information

Active CompaniesRoyan stem cell Technology CoCelltech
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A